NDA 021485 · Orion Pharma
Stalevo 75
Carbidopa, Entacapone, Levodopa · Oral · Aromatic Amino Acid Decarboxylation Inhibitor; Catechol-O-Methyltransferase Inhibitor; Aromatic Amino Acid
Last checked: Nov 20, 2026Latest source record: Mar 19, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2003
Jun 11, 2003
Approved uses
1
Original approval plus efficacy supplements
Registered trials
262
53 Phase 3, 16 recruiting
FAERS reports
481
355 serious, 88 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 19, 2026.
Carbidopa, levodopa and entacapone tablets are indicated for the treatment of Parkinson's disease. Carbidopa, levodopa and entacapone tablets can be used: • To substitute (with equivalent strengths of each of the three components) carbidopa/levodopa and entacapone previously administered as individual products. • To replace carbidopa/levodopa therapy (without entacapone) when patients experience the signs and symptoms of end-of-dose “wearing-off” and when they have been taking a total daily dose of levodopa of 600 mg or less and have not been experiencing dyskinesias. Carbidopa, levodopa and entacapone tablets, a combination drug consisting of levodopa (aromatic amino acid), carbidopa (aromatic amino acid decarboxylation inhibitor), and entacapone (catechol-O-methyltransferase (COMT) inhibitor) is indicated for the treatment of Parkinson's disease. Carbidopa, levodopa and entacapone tablets is to be used: • To substitute (with equivalent strengths of each of the three components) for carbidopa/levodopa and entacapone previously administered as individual products ( 1 ) • To replace carbidopa/levodopa therapy (without entacapone) when patients experience the signs and symptoms of end-of-dose “wearing-off” and when they have been taking a total daily dose of levodopa of 600 mg or less and have not been experiencing dyskinesias ( 1 )
Mechanism: Levodopa Current evidence indicates that symptoms of Parkinson's disease are related to depletion of dopamine in the corpus striatum. Administration of dopamine is ineffective in the treatment of Parkinson's disease because it does not cross the blood-brain barrier. However, levodopa the metabolic precursor of dopamine, does cross the blood-brain barrier, and is presumably converted to dopamine in the brain. This is thought to be the mechanism whereby levodopa relieves the symptoms of Parkinson's disease. Carbidopa When levodopa is administered orally, it is rapidly decarboxylated to dopamine...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 11, 2003 Original approval · Type 4 - New Combination Other Important Information from FDALetterLabel
6 products under this application
- STALEVO 75 · CARBIDOPA 18.75MG; ENTACAPONE 200MG; LEVODOPA 75MG · TABLET, ORAL · Prescription · TE AB
- STALEVO 150 · CARBIDOPA 37.5MG; ENTACAPONE 200MG; LEVODOPA 150MG · TABLET, ORAL · Prescription · TE AB
- STALEVO 50 · CARBIDOPA 12.5MG; ENTACAPONE 200MG; LEVODOPA 50MG · TABLET, ORAL · Prescription · TE AB
- STALEVO 125 · CARBIDOPA 31.25MG; ENTACAPONE 200MG; LEVODOPA 125MG · TABLET, ORAL · Prescription · TE AB
- STALEVO 200 · CARBIDOPA 50MG; ENTACAPONE 200MG; LEVODOPA 200MG · TABLET, ORAL · Prescription · TE AB
- STALEVO 100 · CARBIDOPA 25MG; ENTACAPONE 200MG; LEVODOPA 100MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Carbidopa" as an intervention, any sponsor and status, largest first.
- Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa TherapyPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00099268 · 747 participants · Start Sep 2004 · Primary completion Nov 2008
Drug: Carbidopa/levodopa/entacapone; Immediate release carbidopa/levodopa · For: Parkinson's Disease
Sites: Birmingham, Alabama; Scottsdale, Arizona; La Jolla, California · 73 sites in all
- A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor FluctuationsPivotal-lookingCompleted
Impax Laboratories, LLCIndustry
NCT03670953 · 630 participants · Start Nov 6, 2018 · Primary completion Jun 15, 2021
Drug: IR CD-LD; IPX203 ER CD-LD · For: Parkinson's Disease (Disorder)
Sites: Phoenix, Arizona; Little Rock, Arkansas; Loma Linda, California · 108 sites in all
- An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's DiseasePivotal-lookingCompleted
Impax Laboratories, LLCIndustry
NCT01096186 · 617 participants · Start Mar 2010 · Primary completion Oct 2011
Drug: IPX066 95 mg; IPX066 145 mg and 2 more · For: Parkinson's Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 81 sites in all
- Enhancement of Stroke Rehabilitation With LevodopaPivotal-lookingActive, not recruiting
University Hospital, Basel, SwitzerlandAcademic, hospital or other
NCT03735901 · 610 participants · Start Jun 14, 2019 · Primary completion Aug 27, 2024
Drug: IMP Levodopa 100mg/Carbidopa 25mg; Matching placebo · For: Acute Stroke; Stroke Rehabilitation
Sites: Aarau, Switzerland; Bad Zurzach, Switzerland; Baden, Switzerland · 24 sites in all
- Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" PhenomenonPivotal-lookingCompleted
Bial - Portela C S.A.Industry
NCT01568073 · 600 participants · Start Mar 2011 · Primary completion Nov 2013
Drug: BIA 9-1067; Entacapone and 4 more · For: Parkinson's Disease
Sites: S. Mamede Do Coronado, Portugal
- A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on LevodopaPivotal-lookingCompleted
Kyowa Kirin, Inc.Industry
NCT00199420 · 580 participants · Start Jul 2004 · Primary completion Nov 2005
Drug: Istradefylline (KW-6002) · For: Parkinson's Disease
Sites: Princeton, New Jersey · 2 sites in all
- A Study to Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/LevodopaPivotal-lookingCompleted
NovartisNovartis (NVS)
NCT00134966 · 493 participants · Start Aug 2005 · Primary completion Sep 2007
Drug: capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg) · For: Parkinson's Disease
Sites: Phoenix, Arizona; La Jolla, California; Reseda, California · 60 sites in all
- A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).Pivotal-lookingCompleted
Impax Laboratories, LLCIndustry
NCT00974974 · 471 participants · Start Sep 2009 · Primary completion Jan 2011
Drug: IPX066; IR CD-LD · For: Parkinson's Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 73 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fall69
- death54
- hallucination52
- drug ineffective43
- parkinson^s disease41
- dyskinesia27
- urinary tract infection27
- product dose omission issue25
- confusional state24
- device issue21
- fatigue18
- somnolence18
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2011 | 3 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 4 |
| 2015 | 3 |
| 2016 | 9 |
| 2017 | 34 |
| 2018 | 42 |
| 2019 | 38 |
| 2020 | 61 |
| 2021 | 57 |
| 2022 | 64 |
| 2023 | 60 |
| 2024 | 46 |
| 2025 | 56 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Stalevo 100 (Carbidopa/Levodopa/Entacapone)
2024 spending
$130K
Beneficiaries
16
93 claims
Per beneficiary
$8,126
$7.25 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $15,438 |
| 2021 | $368,257 |
| 2022 | $332,847 |
| 2023 | $228,542 |
| 2024 | $130,010 |
Part D: Stalevo 150 (Carbidopa/Levodopa/Entacapone)
2024 spending
$40K
Beneficiaries
11
41 claims
Per beneficiary
$3,613
$7.58 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $89,994 |
| 2022 | $207,419 |
| 2023 | $127,388 |
| 2024 | $39,744 |
Part D: Stalevo 200 (Carbidopa/Levodopa/Entacapone)
2024 spending
$41K
Beneficiaries
12
41 claims
Per beneficiary
$3,418
$6.66 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $140,274 |
| 2022 | $328,110 |
| 2023 | $151,379 |
| 2024 | $41,016 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial.
Soileau MJ, Aldred J, Budur K, et al. · Lancet Neurol 2022 · Randomized Controlled Trial, Clinical Trial, Phase III
- Levodopa/carbidopa/entacapone (Stalevo).
Hauser RA · Neurology 2004 · Clinical Trial
- Dopamine D1 Agonists: First Potential Treatment for Late-Stage Parkinson's Disease.
Lewis MM, Van Scoy LJ, De Jesus S, et al. · Biomolecules 2023 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Safety and Efficacy of IPX203 in Parkinson's Disease: The RISE-PD Open-Label Extension Study.
Espay AJ, Hauser RA, Dhall R, et al. · Mov Disord 2024 · Randomized Controlled Trial
- Cost-Effectiveness and Cost-Utility of Early Levodopa in Parkinson's Disease.
Verschuur CVM, Suwijn SR, de Haan RJ, et al. · J Parkinsons Dis 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Improved Sleep Correlates with Improved Quality of Life and Motor Symptoms with Foslevodopa/Foscarbidopa.
Chaudhuri KR, Facheris MF, Bergmans B, et al. · Mov Disord Clin Pract 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
Sponsor: Orion Pharma · Also marketed as Stalevo 150, Stalevo 50, Stalevo 125, Stalevo 200, Stalevo 100
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.